Low-level laser therapy


Low-level laser therapy, cold laser therapy or photobiomodulation is a photochemical reaction-based medical treatment that applies low-level lasers or light-emitting diodes to the surface of the body without damaging tissue. Proponents claim that this treatment stimulates healing, relieves pain, and enhances cell function. Sometimes termed as low-level red-light therapy, its effects appear to be limited to a specific range of wavelengths. Its effectiveness is under investigation. Several such devices are cleared by the United States Food and Drug Administration. The therapy may be effective for conditions such as juvenile myopia, rheumatoid arthritis, and oral mucositis.

Mechanism

LLLT makes use of Grotthuss-Draper law, the first law in photochemistry: light must be absorbed by a chemical substance in order for a photochemical reaction to take place. In LLLT that chemical substance is represented by the respiratory enzyme cytochrome c oxidase which is involved in the electron transport chain in mitochondria, which is the generally accepted theory. Administering LLLT below the dose range does not appear to be effective.

Applications

such as those induced by LLLT are well known in biological research.

Human use

Musculoskeletal conditions

LLLT has been promoted for use in treatment of musculoskeletal conditions, including:
LLLT appears to be effective for preventing:
  • oral mucositis in recipients of a stem cell transplant with chemotherapy
  • dentistry

    Brain stimulation

Transcranial photobiomodulation or transcranial low level light therapy is limited in neuromodulation by several factors:
  • Excessive radiation can be harmful. Therefore, dosing must be strictly controlled to achieve growth stimulation, while avoiding excessive singlet oxygen that may be harmful to cells.
  • LED stimulation cannot pass through the skin, only laser light can penetrate deeper tissues and stimulate brain areas. The penetration depth of white and LED light into the skin increases with increasing wavelength from the ultraviolet to the visible light range, and then decreases again in the infrared range. This depth increases if the thickness of the stratum corneum decreases. White light and LED radiation can only penetrate 0.0017 mm to 5 mm of tissue. At wavelengths of 450 nm and 650 nm only 1% of the light reaches approximately 1.6 mm and very little reaches 5 mm.
  • The action spectrum for tissue regeneration and repair consist of more than one wavelength, such that laser and LED light sources may offer some disadvantages, possibly destroying healthy cells. Links between neuronal activity and mental processes are still research questions as is whether the laser reaches only the neuronal structures that benefit from treatment.
Insufficient information from clinical trials compares the effectiveness of different types of devices or device parameters.

Veterinary use

Veterinary clinics use cold laser devices to treat a wide variety of ailments, from arthritis to wounds, on dogs and cats. In spite of this, little research has been done on its effects. According to Brennen McKenzie, president of the Evidence-Based Veterinary Medicine Association, as of 2016 "research into cold laser in dogs and cats is sparse and generally low quality. Most studies are small and have minimal or uncertain controls for bias and error". He allowed that some studies show promising results, while concluding that current evidence is not sufficient to support routine clinical use.

Contraindications

Based on the results of a systematic review, there is no evidence to suggest that people with cancer or people who are at risk of getting cancer should avoid photobiomodulation.

Side effects

There are some reports of mild pain or skin irritation after red-light therapy. The long-term effects on the skin or the hair are not known. Eye protection is suggested for some devices. For skin applications, different wavelengths of light may result in different biological effects depending on the person's skin type, race, and ethnicity. Clinical guidelines suggest that a dermatologist be consulted before undergoing treatment.
For safety, use should be limited to a device approved for human use by the relevant government authority; for example, in the US, it is suggested that only devices certified by the FDA for dermatologic application be used.

Society and culture

History

is believed to be the father of modern light therapy. He used red light to treat smallpox lesions. He received the Nobel Prize in Physiology or Medicine in 1903. Scientific evidence for some of his treatments is lacking, and later eradication of smallpox and development of antibiotics for tuberculosis rendered light therapy obsolete for these diseases.
Hungarian physician and surgeon Endre Mester is credited with the discovery of the biological effects of low power lasers, which occurred a few years after the 1960 invention of the ruby laser and the 1961 invention of the helium–neon laser. Mester accidentally discovered that low-level ruby laser light could regrow hair during an attempt to replicate an experiment that showed that such lasers could reduce tumors in mice. The laser he was using was faulty and was not as powerful as he thought. It failed to affect the tumors, but he noticed that in the places where he had shaved the mice in order to do the experiments, the hair grew back more quickly on the treated mice than on those among the control group. He published those results in 1967. He went on to show that low level HeNe light could accelerate wound healing in mice.
By the 1970s, he was applying low level laser light to treat people with skin ulcers. In 1974, he founded the Laser Research Center at the Semmelweis Medical University in Budapest, and continued working there for the remainder of his life. His sons carried on his work and brought it to the United States. By 1987, companies selling lasers were claiming that they could treat pain, accelerate healing of sports injuries, and treat arthritis, but there was little evidence for this at that time. Mester originally called this approach "laser biostimulation'", but it soon became known as "low-level laser therapy" and with the adaptation of light emitting diodes by those studying this approach, it became known as "low-level light therapy", and to resolve confusion around the exact meaning of "low level", the term "photobiomodulation" arose.

Names

The following terms are accepted as alternatives of low level light therapy term: LLLT, laser biostimulation, laser phototherapy, low-level laser therapy, low-power laser irradiation, low-power laser therapy, and photobiomodulation therapy. The term photobiomodulation therapy is considered the preferred term by industry professionals. However LLLT has been marketed and researched under a number of other terms, including red light therapy, low-power laser therapy, soft laser therapy, low-intensity laser therapy, low-energy laser therapy, cold laser therapy, bio-stimulation laser therapy, photo-biotherapy, therapeutic laser, and monochromatic infrared light energy therapy. More specific applications sometimes have their own terms, for example when administered to acupuncture points, the procedure is called laser acupuncture. When applied to the head, LLLT may be known as transcranial photobiomodulation, transcranial near-infrared laser therapy, or transcranial low level light therapy.

Government action

The FDA filed a complaint for injunction in 2014, alleging that company QLaser PMA were marketing their devices as being able to treat "over 200 different diseases and disorders," including cancer, cardiac arrest, deafness, diabetes, HIV/AIDS, macular degeneration, and venereal disease. This case resulted in a permanent injunction against the manufacture, marketing, sale, and distribution of those devices in 2015.
In 2017, the owner of QLaser, Robert Lytle, and two of QLaser's distributors were charged with a criminal conspiracy to commit fraud. Lytle pleaded guilty to one count of conspiracy to introduce misbranded medical devices into interstate commerce with the intent to defraud and mislead, and one count of criminal contempt in January 2018. Lytle was sentenced to serve 12 years in prison and made an initial restitution payment of $637,000. Lytle's conspirators were sentenced to 24 months and 15 months, respectively.

Reimbursement

and Aetna provide coverage for the prevention of oral mucositis, but not any other reason. The Centers for Medicare and Medicaid Services does not provide coverage for LLLT. Cigna lists LLLT as "experimental, investigational, or unproven for any indication" and provides literature review summaries for a number of conditions.

Research

Musculoskeletal

Evidence does not support a benefit in delayed-onset muscle soreness. It may be useful for muscle pain and injuries. A 2008 Cochrane Library review concluded that LLLT has insufficient evidence for treatment of nonspecific low back pain, a finding echoed in a 2010 review of chronic low back pain. A 2015 review found benefit in nonspecific chronic low-back pain. LLLT may be useful in the treatment of both acute and chronic neck pain. In 2013, however, a systematic review and meta-analysis of LLLT for neck pain indicated that the benefit was not of significant importance and that the evidence had a high risk of bias. In a study testing the efficacy of low-level laser therapy treating plantar fasciitis found that LLLT significantly reduces pain in lower extremity tendinopathy and plantar fasciitis in the short and medium terms. The same study also stated that while comparing the effect of LLLT to that of therapeutic ultrasound in persons with patellar tendinopathy, and they found a statistically significant effect in favour of LLLT, both on pain reduction and function.
There are tentative data that LLLT is useful in the short-term treatment of pain caused by rheumatoid arthritis, and possibly chronic joint disorders. Research that compared the effects of LLLT against other treatments, sham treatments, or no treatment at all, and randomized adult patients with rheumatoid arthritis to receive it were considered. These outcomes included pain, functional capacity, adverse events, inflammation, disease activity, range of motion, stiffness in the morning, muscle strength, and quality of life. The findings indicate that the differences between utilizing a sham and an infrared laser may be negligible or nonexistent in terms of pain, stiffness in the morning, grip strength, functional ability, inflammation, range of motion, disease activity, and side events. It was also discovered that the data about the effects of laser acupuncture against reflexology in terms of functional ability, quality of life, and inflammation is quite hazy, and about the effects of red laser versus sham in terms of pain, morning stiffness, and side events. The usefulness of red laser, laser acupuncture, and reflexology in the treatment of RA patients is not well enough demonstrated. A 2019 systematic review and meta-analysis found evidence for pain reduction in osteoarthritis. While it does not appear to improve pain in temporomandibular disorders, it may improve function.
There is tentative evidence of benefit in tendinopathy. A 2014 review found benefit in shoulder tendinopathy. A 2014 Cochrane review found tentative evidence that it may help in frozen shoulders.